المؤلفون: Letarouilly, Jean-Guillaume, Pham, Thao, Pierache, Adeline, Acquacalda, Émilie, Banneville, Béatrice, Barbarot, Sébastien, Baudart, Pauline, Bauer, Élodie, Claudepierre, Pascal, Constantin, Arnaud, Dernis, Emmanuelle, Felten, Renaud, Gaudin, Philippe, Girard, Céline, Gombert, Bruno, Goupille, Philippe, Guennoc, Xavier, Henry-Desailly, Isabelle, Jullien, Denis, Karimova, Elena, Lanot, Sylvain, Le Dantec, Loïc, Pascart, Tristan, Plastaras, Laurianne, Sultan, Nathalie, Truchet, Xavier, Varin, Stéphane, Wendling, Daniel, Gaboriau, Louise, Staumont-Sallé, Delphine, Peyrin-Biroulet, Laurent, Flipo, René-Marc

المساهمون: Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Physiopathologie des Adaptations Nutritionnelles (PhAN), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Pathogenesis and Control of Chronic and Emerging Infections (PCCEI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université des Antilles (UA)-Etablissement français du don du sang Montpellier -Université de Montpellier (UM), Marrow Adiposity & Bone Lab - Adiposité Médullaire et Os - ULR 4490 (MABLab (ex-pmoi)), Université du Littoral Côte d'Opale (ULCO)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Service d'Hépato-gastro-entérologie CHRU Nancy, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)

المصدر: ISSN: 1462-0324.

مصطلحات موضوعية: IBD, IL-17 inhibitor, PsA, psoriasis, real-world, secukinumab, spondyloarthritis, [SDV]Life Sciences [q-bio], [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology

الوصف: International audience ; Objectives To describe new-onset IBD (new IBD) in patients treated with IL-17 inhibitors (IL-17i), to assess their incidence and to identify their risk factors in real life. Methods A French national registry (MISSIL) aimed to report all cases of new IBD in patients treated with IL-17i from January 2016 to December 2019. Using the estimated number of patients treated by IL-17 in France during the study period, the annual incidence rates of new IBD was reported in IL-17i-treated patients. A case–control study was performed with two controls per new IBD case matched by gender, age and underlying inflammatory disease. Results Thirty-one cases of new IBD under IL-17i were collected: 27 patients treated for spondyloarthritis and four patients for psoriasis. All were observed with secukinumab (SEK). The median time to onset of new IBD symptoms was 4.0 (1.5–7.5) months. SEK was discontinued in all patients. The evolution was favourable with complete resolution (17/31), improvement (7/31) or stabilization (5/31). Two patients died: one due to a massive myocardial infarction and one due to post-colectomy complications. The incidence of new IBD decreased from 0.69/100 patient-years [PY] (7/1010) in 2016 to 0.08/100 PY (6/7951) in 2019. No previous treatment with etanercept (odds ratio [OR] = 0.33, 95% CI: 0.14–0.80, P = 0.014) and low number of previous biologic therapies (OR = 0.67, 95% CI: 0.47, 0.94, P = 0.021) were significantly associated with new IBD. Conclusion The incidence of new IBD was low and decreased from 2016 to 2019. The outcome was favourable in 24 out of 31 patients, but two patients died.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34730790; hal-03979878; https://hal.science/hal-03979878Test; PUBMED: 34730790

الإتاحة: https://doi.org/10.1093/rheumatology/keab819Test
https://hal.science/hal-03979878Test

المؤلفون: Letarouilly, Jean-Guillaume, Pham, Thao, Pierache, Adeline, Acquacalda, Émilie, Banneville, Béatrice, Barbarot, Sébastien, Baudart, Pauline, Bauer, Élodie, Claudepierre, Pascal, Constantin, Arnaud, Dernis, Emmanuelle, Felten, Renaud, Gaudin, Philippe, Girard, Céline, Gombert, Bruno, Goupille, Philippe, Guennoc, Xavier, Henry-Desailly, Isabelle, Jullien, Denis, Karimova, Elena, Lanot, Sylvain, Le Dantec, Loïc, Pascart, Tristan, Plastaras, Laurianne, Sultan, Nathalie, Truchet, Xavier, Varin, Stéphane, Wendling, Daniel, Gaboriau, Louise, Staumont-Sallé, Delphine, Peyrin-Biroulet, Laurent, Flipo, René-Marc

المصدر: Rheumatology ; volume 61, issue 7, page 2848-2855 ; ISSN 1462-0324 1462-0332

مصطلحات موضوعية: Pharmacology (medical), Rheumatology

الوصف: Objectives To describe new-onset IBD (new IBD) in patients treated with IL-17 inhibitors (IL-17i), to assess their incidence and to identify their risk factors in real life. Methods A French national registry (MISSIL) aimed to report all cases of new IBD in patients treated with IL-17i from January 2016 to December 2019. Using the estimated number of patients treated by IL-17 in France during the study period, the annual incidence rates of new IBD was reported in IL-17i-treated patients. A case–control study was performed with two controls per new IBD case matched by gender, age and underlying inflammatory disease. Results Thirty-one cases of new IBD under IL-17i were collected: 27 patients treated for spondyloarthritis and four patients for psoriasis. All were observed with secukinumab (SEK). The median time to onset of new IBD symptoms was 4.0 (1.5–7.5) months. SEK was discontinued in all patients. The evolution was favourable with complete resolution (17/31), improvement (7/31) or stabilization (5/31). Two patients died: one due to a massive myocardial infarction and one due to post-colectomy complications. The incidence of new IBD decreased from 0.69/100 patient-years [PY] (7/1010) in 2016 to 0.08/100 PY (6/7951) in 2019. No previous treatment with etanercept (odds ratio [OR] = 0.33, 95% CI: 0.14–0.80, P = 0.014) and low number of previous biologic therapies (OR = 0.67, 95% CI: 0.47, 0.94, P = 0.021) were significantly associated with new IBD. Conclusion The incidence of new IBD was low and decreased from 2016 to 2019. The outcome was favourable in 24 out of 31 patients, but two patients died.

الإتاحة: https://doi.org/10.1093/rheumatology/keab819Test
https://academic.oup.com/rheumatology/article-pdf/61/7/2848/44473607/keab819.pdfTest

المؤلفون: Brocq, Olivier, Acquacalda, Emilie, Florent, Amélie, Lascar, Tristan

المصدر: Joint Bone Spine ; volume 87, issue 1, page 103-104 ; ISSN 1297-319X

مصطلحات موضوعية: Rheumatology

الإتاحة: https://doi.org/10.1016/j.jbspin.2019.09.003Test
https://api.elsevier.com/content/article/PII:S1297319X19301228?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1297319X19301228?httpAccept=text/plainTest

المؤلفون: Brocq, Olivier, Acquacalda, Emilie, Florent, Amélie, Lascar, Tristan

المصدر: Revue du Rhumatisme ; volume 86, issue 6, page 647-648 ; ISSN 1169-8330

مصطلحات موضوعية: Rheumatology

الإتاحة: https://doi.org/10.1016/j.rhum.2019.07.020Test
https://api.elsevier.com/content/article/PII:S116983301930170X?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S116983301930170X?httpAccept=text/plainTest

المؤلفون: Acquacalda, Emilie, Roux, Christian Hubert, Albert, Christine, Breuil, Véronique, Passeron, Thierry, Euller-Ziegler, Liana

المصدر: Joint Bone Spine ; volume 82, issue 5, page 362-364 ; ISSN 1297-319X

مصطلحات موضوعية: Rheumatology

الإتاحة: https://doi.org/10.1016/j.jbspin.2015.01.020Test
https://api.elsevier.com/content/article/PII:S1297319X1500038X?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1297319X1500038X?httpAccept=text/plainTest

المؤلفون: Acquacalda, Émilie, Roux, Christian Hubert, Albert, Christine, Breuil, Véronique, Passeron, Thierry, Euller-Ziegler, Liana

المصدر: Revue du Rhumatisme ; volume 82, issue 6, page 411-413 ; ISSN 1169-8330

مصطلحات موضوعية: Rheumatology

الإتاحة: https://doi.org/10.1016/j.rhum.2015.07.006Test
https://api.elsevier.com/content/article/PII:S1169833015001453?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1169833015001453?httpAccept=text/plainTest

المؤلفون: Acquacalda, Emilie, Albert, Christine, Montaudie, Henri, Fontas, Eric, Danre, Agnes, Roux, Christian Hubert, Breuil, Véronique, Lacour, Jean Philippe, Passeron, Thierry, Euller Ziegler, Liana

المصدر: Joint Bone Spine ; volume 82, issue 4, page 267-271 ; ISSN 1297-319X

مصطلحات موضوعية: Rheumatology

الإتاحة: https://doi.org/10.1016/j.jbspin.2015.01.016Test
https://api.elsevier.com/content/article/PII:S1297319X15000342?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1297319X15000342?httpAccept=text/plainTest

المؤلفون: Acquacalda, Emilie, Albert, Christine, Montaudie, Henri, Fontas, Eric, Danre, Agnes, Roux, Christian Hubert, Breuil, Véronique, Lacour, Jean Philippe, Passeron, Thierry, Ziegler, Liana Euller

المصدر: Revue du Rhumatisme ; volume 82, issue 5, page 312-316 ; ISSN 1169-8330

مصطلحات موضوعية: Rheumatology

الإتاحة: https://doi.org/10.1016/j.rhum.2015.04.013Test
https://api.elsevier.com/content/article/PII:S1169833015001015?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1169833015001015?httpAccept=text/plainTest

المؤلفون: Brocq, Olivier, Acquacalda, Émilie, Berthier, Frédéric, Albert, Christine, Bolla, Gilles, Millasseau, Élodie, Destombe, Claire, Azulay, Johanna, Asquier, Caroline, Florent, Amélie, Le Seaux, Sylvie, Euller-Ziegler, Liana

المصدر: Revue du Rhumatisme ; volume 82, issue 3, page 179-183 ; ISSN 1169-8330

مصطلحات موضوعية: Rheumatology

الإتاحة: https://doi.org/10.1016/j.rhum.2015.02.004Test
https://api.elsevier.com/content/article/PII:S1169833015000411?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1169833015000411?httpAccept=text/plainTest

المؤلفون: Brocq, Olivier¹ obrocq@chpg.mc, Acquacalda, Emilie², Berthier, Frédéric³, Albert, Christine², Bolla, Gilles⁴, Millasseau, Elodie⁵, Destombe, Claire⁵, Azulay, Johanna⁴, Asquier, Caroline⁴, Florent, Amélie², Le Seaux, Sylvie⁵, Euller-Ziegler, Liana²

المصدر: Joint Bone Spine. Mar2016, Vol. 83 Issue 2, p155-159. 5p.

مصطلحات موضوعية: *RHEUMATOID arthritis treatment, *INFLUENZA vaccines, *PNEUMOCOCCAL vaccines, *BIOTHERAPY, *SPONDYLOARTHROPATHIES, *PRIMARY care, *THERAPEUTICS, *INFLUENZA prevention, *STREPTOCOCCAL disease prevention, *INFLUENZA, *RHEUMATOID arthritis, *STREPTOCOCCAL diseases, *CROSS-sectional method, *RETROSPECTIVE studies, *DISEASE complications

مستخلص: Objectives: To evaluate influenza and pneumococcal vaccine coverage in patients taking biological therapy for chronic inflammatory joint disease and to identify factors associated with the decision to administer these two vaccines.Methods: Retrospective cross-sectional questionnaire study of a cohort of 584 patients taking biological therapy for chronic inflammatory joint disease (rheumatoid arthritis or spondyloarthritis). We studied the influenza and pneumococcal vaccine coverage rates, information about these vaccines given to patients by the primary-care physician and rheumatologist, and reasons for not administering the vaccines.Results: Overall vaccine coverage rates were 44% for influenza and 62% for pneumococcus. Factors associated with being vaccinated were patient age, previous influenza vaccination, and patient information. Concern about adverse effects and absence of patient information by the primary-care physician and rheumatologist were associated with very low coverage rates.Conclusion: This study showed insufficient vaccine coverage rates, particularly against influenza, in a population at high risk because of exposure to biological therapy. Patient information by healthcare professionals about influenza and pneumococcal vaccination has a major impact and should be renewed as often as possible. [ABSTRACT FROM AUTHOR]